Edition:
United States

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

5.92USD
16 Feb 2018
Change (% chg)

$-1.04 (-14.94%)
Prev Close
$6.96
Open
$6.83
Day's High
$7.00
Day's Low
$5.86
Volume
49,699
Avg. Vol
15,922
52-wk High
$12.00
52-wk Low
$3.61

Chart for

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate,... (more)

Overall

Beta: 2.80
Market Cap(Mil.): $89.33
Shares Outstanding(Mil.): 15.09
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Galmed Announces Arrive Study Data

* TOP-LINE RESULTS FROM ARRIVE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT

Feb 14 2018

BRIEF-Galmed Pharmaceuticals To Provide Corporate Update At The Leerink Partners 7Th Annual Global Healthcare Conference

* GALMED PHARMACEUTICALS TO PROVIDE CORPORATE UPDATE AT THE LEERINK PARTNERS 7TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Source text for Eikon: Further company coverage:

Feb 08 2018

BRIEF-Israeli Tax Authority Issues Tax Ruling On Galmed Pharma's Unit

* GALMED PHARMACEUTICALS -ISRAELI TAX AUTHORITY ISSUED TAX RULING GRANTING CO'S UNIT "PREFERRED TECHNOLOGICAL ENTERPRISE" STATUS, SUBJECT TO CONDITIONS

Feb 07 2018

BRIEF-Galmed Pharma Raised Gross Proceeds Of $11.6 Mln Under ATM Programs During Dec. 2017

* GALMED PHARMACEUTICALS RAISED GROSS PROCEEDS OF $11.6 MILLION UNDER ATM PROGRAMS DURING DECEMBER 2017 Source text for Eikon: Further company coverage:

Jan 02 2018

BRIEF-683 Capital Management Llc Reports 5.1 Pct Passive Stake In Galmed Pharmaceuticals Ltd As Of Dec 6

* 683 CAPITAL MANAGEMENT LLC REPORTS 5.1 PERCENT PASSIVE STAKE IN GALMED PHARMACEUTICALS LTD AS OF DEC 6 - SEC FILING Source text: (http://bit.ly/2oG4CRl) Further company coverage:

Dec 18 2017

BRIEF-Galmed Pharmaceuticals Q3 loss per share $0.23

* Galmed Pharmaceuticals reports third quarter 2017 financial results and provides business update

Nov 09 2017

BRIEF-Galmed Pharmaceuticals announces ‍publication of a paper entitled "role of aramchol in steatohepatitis and fibrosis in mice"

* Galmed Pharmaceuticals Ltd - ‍publication of a paper entitled "role of aramchol in steatohepatitis and fibrosis in mice" in hepatology communications

Oct 05 2017

Earnings vs. Estimates